Get the Stockscreener App
12.35
1.23%
0.15
After Hours:
12.41
0.06
+0.49%
Intellia Therapeutics Inc stock is traded at $12.35, with a volume of 7.92M.
It is up +1.23% in the last 24 hours and down -14.36% over the past month.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$12.20
Open:
$12.155
24h Volume:
7.92M
Relative Volume:
1.43
Market Cap:
$1.73B
Revenue:
$67.67M
Net Income/Loss:
$-412.69M
P/E Ratio:
-3.2274
EPS:
-3.8266
Net Cash Flow:
$-395.87M
1W Performance:
-16.27%
1M Performance:
-14.36%
6M Performance:
+29.32%
1Y Performance:
+47.55%
1-Day Range:
$11.81
$12.45
1-Week Range:
$11.81
$14.79
52-Week Range:
$7.95
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.35 | 1.70B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-11-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-28-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-27-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-27-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bhanji Muna - Moomoo
Intellia (NTLA) director receives 9,200 RSUs and 13,300 options - Stock Titan
Intellia (NTLA) director Georgia Keresty receives stock awards and options grant - Stock Titan
Intellia Therapeutics (NTLA) director receives stock and option awards - Stock Titan
Intellia (NTLA) director Brian Goff receives RSU and stock option grants - Stock Titan
Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options - Stock Titan
Intellia (NTLA) director awarded RSUs and stock options in new grant - Stock Titan
Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options - Stock Titan
Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound? - MSN
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Singapore
Draft FDA guidance could be a boon for gene therapy developers - MSN
Intellia Therapeutics Stock Short Interest Rises to 46.78% - Quiver Quantitative
Intellia Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Intellia Therapeutics, Inc. Trade Ideas — XETR:38I - TradingView
Average basic shares outstanding of Intellia Therapeutics, Inc. – XETR:38I - TradingView
Lonvo-z Phase 3 Allergy Congress Data Might Change The Case For Investing In Intellia Therapeutics (NTLA) - Sahm
Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution - Yahoo Finance
Understanding Momentum Shifts in (NTLA) - Stock Traders Daily
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
New Intellia hires receive 47,150 RSUs in Nasdaq inducement plan - Stock Titan
NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update - Insider Monkey
NTLA Stock Climbs As Phase 3 Wins Meet Extended Cash Runway - StocksToTrade
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't - The Motley Fool
A Look At Intellia Therapeutics (NTLA) Valuation As Phase 3 HAELO Gene Editing Data Approaches - Sahm
Intellia to present Phase 3 gene editing trial data at congress - Investing.com UK
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - Intellia Therapeutics
Intellia to present Phase 3 gene editing trial data at congress By Investing.com - Investing.com South Africa
Intellia Therapeutics to Present Phase 3 HAELO Trial Data for Lonvo-z at EAACI Annual Congress 2026 - Quiver Quantitative
CRISPR HAE therapy lonvo-z gets late-breaking EAACI 2026 slot - Stock Titan
Intellia TherapeuticsSteady Progress, Historic Commercial Approval In Sight - Seeking Alpha
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout
Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift - Sahm
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29 - Moomoo
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now? - TradingView
Avoiding Lag: Real-Time Signals in (NTLA) Movement - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - MSN
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Investing News Network
Intellia Drops Counterclaims In Gene-Editing Patent Case - Law360
Intellia Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit - Bloomberg Law News
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test By Investing.com - Investing.com Nigeria
Intellia’s CRISPR Submission Is a Regulatory Stress Test the FDA Has Never Faced Before - The Clinical Trial Vanguard
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test - Investing.com
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - TradingView
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise? - Sahm
Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win - CoinCentral
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.65%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):